person · Reporting owner

RIESCHEL GARY E

Disclosed activity across 2 companies

Tapewire entity: 92115
SEC CIK: 0001248153

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
LanzaTech Global, Inc.LNZA · Entity 6952	Director	February 08, 2024	April 09, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

LanzaTech Global, Inc.

Report date February 08, 2024 · Filed April 09, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	20,000	Reported balance After 2024-02-08 transaction · row 1 1 source row Row 1 · 2024-02-08 · Exercise / conversion · Acquired 20,000 · Balance 20,000 F1: Restricted Stock Units (RSUs) convert into shares of LanzaTech Global Inc. common stock, $.0001 par value, on a one-for-one basis.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-02-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-02-08 · Exercise / conversion · Disposed 20,000 · Balance 0 F1: Restricted Stock Units (RSUs) convert into shares of LanzaTech Global Inc. common stock, $.0001 par value, on a one-for-one basis. F2: On May 2, 2023, the Reporting Person was granted 20,000 RSUs, which vested in full on February 8, 2024.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	32,467	Reported balance After 2024-04-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-04-06 · Grant · Acquired 32,467 · Balance 32,467 F3: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of LanzaTech Global, Inc. (the "Company"). Subject to the terms of the RSU Agreement, the RSUs will vest in full on March 6, 2025.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted Stock Units (RSUs) convert into shares of LanzaTech Global Inc. common stock, $.0001 par value, on a one-for-one basis.

F2: On May 2, 2023, the Reporting Person was granted 20,000 RSUs, which vested in full on February 8, 2024.

F3: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of LanzaTech Global, Inc. (the "Company"). Subject to the terms of the RSU Agreement, the RSUs will vest in full on March 6, 2025.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Jasper Therapeutics, Inc.

Report date January 27, 2023 · Filed April 11, 2023

Jointly reported with Qiming U.S. Healthcare Fund II, L.P., Qiming U.S. Healthcare GP II, LLC, MCDADE MARK

Section 16 reporting ended · disclosed 2023-04-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Voting Common StockSEC Table I · non-derivative	Direct	8,519,648	Reported balance After 2023-01-27 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-01-27 · Purchase · Acquired 2,666,666 · Balance 8,519,648 F1: The securities are directly held by Qiming U.S. Healthcare Fund II, L.P. ("Qiming"). The general partner of Qiming is Qiming U.S. Healthcare GP II, LLC ("Qiming GP"). Gary Rieschel and Mark McDade are the managing partners of Qiming GP and may be deemed to share voting and dispositive power over the shares held by Qiming. Each of Qiming GP and Messrs. Rieschel and McDade disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The securities are directly held by Qiming U.S. Healthcare Fund II, L.P. ("Qiming"). The general partner of Qiming is Qiming U.S. Healthcare GP II, LLC ("Qiming GP"). Gary Rieschel and Mark McDade are the managing partners of Qiming GP and may be deemed to share voting and dispositive power over the shares held by Qiming. Each of Qiming GP and Messrs. Rieschel and McDade disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 06, 2024 Filed Apr 9, 2024 21:46 UTC	LanzaTech Global, Inc. LNZA · Entity 6952	GrantRestricted Stock Units · Derivative	32,467	$0.00	$0.00	Disclosure SEC source: 0001628280-24-015524 · wk-form4_1712713551.xml · derivative · entry 3 RIESCHEL GARY E · CIK 0001248153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,467 Underlying: Common Stock · 32,467 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of LanzaTech Global, Inc. (the "Company"). Subject to the terms of the RSU Agreement, the RSUs will vest in full on March 6, 2025. F3 · derivative.exercise_date: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of LanzaTech Global, Inc. (the "Company"). Subject to the terms of the RSU Agreement, the RSUs will vest in full on March 6, 2025. F3 · derivative.expiration_date: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of LanzaTech Global, Inc. (the "Company"). Subject to the terms of the RSU Agreement, the RSUs will vest in full on March 6, 2025. Read SEC document
February 08, 2024 Filed Apr 9, 2024 21:46 UTC	LanzaTech Global, Inc. LNZA · Entity 6952	Exercise / conversionRestricted Stock Units · Derivative	20,000	$0.00	$0.00	Disclosure SEC source: 0001628280-24-015524 · wk-form4_1712713551.xml · derivative · entry 2 RIESCHEL GARY E · CIK 0001248153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units (RSUs) convert into shares of LanzaTech Global Inc. common stock, $.0001 par value, on a one-for-one basis. F2 · derivative.exercise_date: On May 2, 2023, the Reporting Person was granted 20,000 RSUs, which vested in full on February 8, 2024. F2 · derivative.expiration_date: On May 2, 2023, the Reporting Person was granted 20,000 RSUs, which vested in full on February 8, 2024. Read SEC document
February 08, 2024 Filed Apr 9, 2024 21:46 UTC	LanzaTech Global, Inc. LNZA · Entity 6952	Exercise / conversionCommon Stock	20,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-24-015524 · wk-form4_1712713551.xml · nonDerivative · entry 1 RIESCHEL GARY E · CIK 0001248153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units (RSUs) convert into shares of LanzaTech Global Inc. common stock, $.0001 par value, on a one-for-one basis. Read SEC document
May 02, 2023 Filed May 4, 2023 21:00 UTC	LanzaTech Global, Inc. LNZA · Entity 6952	GrantRestricted Stock Units · Derivative	20,000	$0.00	$0.00	Disclosure SEC source: 0001628280-23-015960 · wf-form4_168324842018733.xml · derivative · entry 1 RIESCHEL GARY E · CIK 0001248153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of LanzaTech Global, Inc. (the "Company"). Subject to the terms of the RSU Agreement, the RSUs will vest in full on February 8, 2024. F1 · derivative.exercise_date: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of LanzaTech Global, Inc. (the "Company"). Subject to the terms of the RSU Agreement, the RSUs will vest in full on February 8, 2024. F1 · derivative.expiration_date: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of LanzaTech Global, Inc. (the "Company"). Subject to the terms of the RSU Agreement, the RSUs will vest in full on February 8, 2024. Read SEC document
January 27, 2023 Filed Apr 11, 2023 19:55 UTC	Jasper Therapeutics, Inc. JSPR · Entity 7588	PurchaseVoting Common Stock	2,666,666	$1.50	$3,999,999.00	Disclosure SEC source: 0001209191-23-024058 · doc4.xml · nonDerivative · entry 1 Qiming U.S. Healthcare Fund II, L.P. · CIK 0001765710 · 10% owner Qiming U.S. Healthcare GP II, LLC · CIK 0001868862 · 10% owner MCDADE MARK · CIK 0001242126 · 10% owner RIESCHEL GARY E · CIK 0001248153 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,519,648 F1 · ownership.direct: The securities are directly held by Qiming U.S. Healthcare Fund II, L.P. ("Qiming"). The general partner of Qiming is Qiming U.S. Healthcare GP II, LLC ("Qiming GP"). Gary Rieschel and Mark McDade are the managing partners of Qiming GP and may be deemed to share voting and dispositive power over the shares held by Qiming. Each of Qiming GP and Messrs. Rieschel and McDade disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.